$OM
Outset Medical, Inc. Stock $om

$om Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000095017022013857 Filed on August 02, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$27.76M	$25.06M	$30.55M
YoY Change	5.48%	-0.63%	33.31%
Cost Of Revenue	$23.43M	$21.28M	$26.11M
YoY Change	0.23%	-11.96%	15.38%
Gross Profit	$4.336M	$3.782M	$4.442M
YoY Change	47.18%	259.51%	1437.02%
Gross Profit Margin	15.62%	15.09%	14.54%
Selling, General & Admin	$32.28M	$33.98M	$30.09M
YoY Change	38.2%	48.22%	34.34%
% of Gross Profit	744.37%	898.52%	677.31%
Research & Development	$13.06M	$13.52M	$10.83M
YoY Change	34.23%	68.34%	43.08%
% of Gross Profit	301.18%	357.51%	243.83%
Depreciation & Amortization	$1.314M	$1.324M	$1.262M
YoY Change	0.08%	1.61%	1.28%
% of Gross Profit	30.3%	35.01%	28.41%
Operating Expenses	$45.34M	$47.50M	$40.92M
YoY Change	37.03%	53.44%	36.55%
Operating Profit	-$41.00M	-$43.72M	-$36.48M
YoY Change	36.04%	46.19%	22.91%
Interest Expense	$567.0K	$481.0K	$422.0K
YoY Change	31.55%	11.6%	0.0%
% of Operating Profit
Other Income/Expense, Net	$805.0K	$459.0K	$120.0K
YoY Change	713.13%	179.88%	7.14%
Pretax Income	-$40.76M	-$43.74M	-$36.78M
YoY Change	33.77%	44.97%	22.65%
Income Tax	$20.00K	$96.00K	$115.0K
% Of Pretax Income
Net Earnings	-$40.78M	-$43.84M	-$36.89M
YoY Change	33.84%	45.12%	22.87%
Net Earnings / Revenue	-146.9%	-174.96%	-120.76%
Basic Earnings Per Share	-$0.85	-$0.92	-$0.78
Diluted Earnings Per Share	-$0.85	-$0.92	-$776.9K
COMMON SHARES
Basic Shares Outstanding	48.01M	47.88K	47.41M
Diluted Shares Outstanding	48.13K	47.88K	47.49K

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$227.5M	$262.1M	$302.3M
YoY Change	-39.01%	-33.86%	8.93%
Cash & Equivalents	$63.88M	$75.50M	$114.3M
Short-Term Investments	$163.6M	$186.6M	$187.9M
Other Short-Term Assets	$4.714M	$5.399M	$5.387M
YoY Change	-29.21%	-16.41%	-29.12%
Inventory	$55.26M	$53.69M	$42.87M
Prepaid Expenses
Receivables	$22.51M	$24.63M	$26.90M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$310.0M	$345.8M	$377.4M
YoY Change	-28.46%	-22.81%	17.32%
LONG-TERM ASSETS
Property, Plant & Equipment	$15.62M	$15.25M	$13.88M
YoY Change	7.47%	-33.8%	-41.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$386.0K	$216.0K	$161.0K
YoY Change	132.53%	-99.36%	-87.02%
Total Long-Term Assets	$55.72M	$55.46M	$54.32M
YoY Change	0.39%	-2.45%	-6.56%
TOTAL ASSETS
Total Short-Term Assets	$310.0M	$345.8M	$377.4M
Total Long-Term Assets	$55.72M	$55.46M	$54.32M
Total Assets	$365.7M	$401.2M	$431.7M
YoY Change	-25.18%	-20.52%	13.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.444M	$2.753M	$5.149M
YoY Change	-46.56%	16.46%	-22.58%
Accrued Expenses	$34.04M	$36.97M	$30.79M
YoY Change	14.0%	56.84%	38.07%
Deferred Revenue	$7.825M	$7.752M	$6.833M
YoY Change	50.13%		93.02%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$1.000M
YoY Change
Total Short-Term Liabilities	$49.64M	$55.24M	$48.89M
YoY Change	19.9%	55.86%	40.41%
LONG-TERM LIABILITIES
Long-Term Debt	$29.83M	$28.81M	$29.78M
YoY Change	0.3%	-3.07%	0.3%
Other Long-Term Liabilities	$7.147M	$7.426M	$7.615M
YoY Change	-9.62%	-12.53%	-12.47%
Total Long-Term Liabilities	$29.83M	$28.81M	$29.78M
YoY Change	0.3%	-3.07%	0.3%
TOTAL LIABILITIES
Total Short-Term Liabilities	$49.64M	$55.24M	$48.89M
Total Long-Term Liabilities	$29.83M	$28.81M	$29.78M
Total Liabilities	$86.62M	$91.47M	$86.29M
YoY Change	9.57%	24.2%	17.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$747.5M	-$706.7M	-$662.9M
YoY Change	27.82%	27.49%
Common Stock	$1.028B	$1.017B	$1.009B
YoY Change	3.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$279.1M	$309.8M	$345.5M
YoY Change
Total Liabilities & Shareholders Equity	$365.7M	$401.2M	$431.7M
YoY Change	-25.18%	-20.52%	13.68%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$40.78M	-$43.84M	-$36.89M
YoY Change	33.84%	45.12%	22.87%
Depreciation, Depletion And Amortization	$1.314M	$1.324M	$1.262M
YoY Change	0.08%	1.61%	1.28%
Cash From Operating Activities	-$34.31M	-$38.57M	-$38.34M
YoY Change	21.97%	25.09%	-0.73%
INVESTING ACTIVITIES
Capital Expenditures	-$2.741M	-$1.997M	$1.478M
YoY Change	458.25%	136.05%	60.83%
Acquisitions
YoY Change
Other Investing Activities	$22.90M	$681.0K	-$31.91M
YoY Change	-207.36%	-100.7%	441.8%
Cash From Investing Activities	$20.16M	-$1.316M	-$33.39M
YoY Change	-192.38%	-98.65%	390.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.533M	1.042M	3.723M
YoY Change	-59.06%	-99.31%	67.85%
NET CHANGE
Cash From Operating Activities	-34.31M	-38.57M	-38.34M
Cash From Investing Activities	20.16M	-1.316M	-33.39M
Cash From Financing Activities	2.533M	1.042M	3.723M
Net Change In Cash	-11.62M	-38.85M	-68.00M
YoY Change	-73.45%	-272.57%	57.39%
FREE CASH FLOW
Cash From Operating Activities	-$34.31M	-$38.57M	-$38.34M
Capital Expenditures	-$2.741M	-$1.997M	$1.478M
Free Cash Flow	-$31.57M	-$36.58M	-$39.81M
YoY Change	14.22%	21.96%	0.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	579000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	276000
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-570000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	684000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	8366000
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1508000
	om	Increase Decrease In Accrued Warranty Liability IncreaseDecreaseInAccruedWarrantyLiability	-260000
	om	Increase Decrease In Accrued Warranty Liability IncreaseDecreaseInAccruedWarrantyLiability	160000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1305000
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1117000
	om	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-548000
	om	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-360000
	dei	Amendment Flag AmendmentFlag	false
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39513
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
	dei	Entity Registrant Name EntityRegistrantName	Outset Medical, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-0514392
	dei	Entity Address Address Line1 EntityAddressAddressLine1	3052 Orchard Dr.
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Jose
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95134
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47997000
	dei	City Area Code CityAreaCode	669
	om	Provision For Inventories ProvisionForInventories	325000
	dei	Local Phone Number LocalPhoneNumber	231-8200
	om	Other Non Cash Items OtherNonCashItems	29000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	OM
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48007301
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75497000
	om	Other Non Cash Items OtherNonCashItems	5000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	182348000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-964000
CY2022Q2	us-gaap	Short Term Investments ShortTermInvestments	186565000
CY2021Q4	us-gaap	Short Term Investments ShortTermInvestments	157140000
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24627000
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	25600000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9946000
CY2021Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	3704000
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	7752000
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6340000
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1235000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1151000
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1000000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	55240000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	51695000
CY2022Q2	om	Accrued Interest Noncurrent AccruedInterestNoncurrent	960000
CY2021Q4	om	Accrued Interest Noncurrent AccruedInterestNoncurrent	721000
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	205000
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	312000
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6261000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6893000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5529000
CY2022Q2	us-gaap	Assets Current AssetsCurrent	345777000
CY2022Q2	us-gaap	Inventory Net InventoryNet	53689000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	409802000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	33311000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	33311000
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15245000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12964000
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6687000
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7231000
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	216000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	156000
CY2022Q2	us-gaap	Assets Assets	401236000
CY2021Q4	us-gaap	Assets Assets	463464000
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2753000
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1763000
CY2022Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	15795000
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	24948000
CY2022Q2	om	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	23261000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001484612
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q4	us-gaap	Inventory Net InventoryNet	39185000
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5399000
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q4	om	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13789000
CY2022Q2	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	3444000
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28806000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	29762000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15602000
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	23198000
CY2022Q2	us-gaap	Liabilities Liabilities	91472000
CY2021Q4	us-gaap	Liabilities Liabilities	89383000
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47997000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47241000
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47241000
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	48000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	47000
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1017396000
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1000212000
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-955000
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-184000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-706725000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-625994000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	309764000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	374081000
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	401236000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	463464000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25057000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25216000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55607000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48132000
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21275000
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	24164000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	47383000
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	46791000
CY2022Q2	us-gaap	Gross Profit GrossProfit	3782000
CY2021Q2	us-gaap	Gross Profit GrossProfit	1052000
	us-gaap	Gross Profit GrossProfit	8224000
	us-gaap	Gross Profit GrossProfit	1341000
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13521000
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8032000
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9722000
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	4017000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20493000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	18968000
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13204000
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	43575000
CY2022Q2	us-gaap	Interest Expense InterestExpense	481000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24352000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-80196000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-59582000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44228
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	459000
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	164000
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	44228
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	26353000
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10784000
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	47503000
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	30958000
	us-gaap	Operating Expenses OperatingExpenses	88420000
	us-gaap	Operating Expenses OperatingExpenses	60923000
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-43721000
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-29906000
CY2021Q2	us-gaap	Interest Expense InterestExpense	431000
	us-gaap	Interest Expense InterestExpense	903000
	us-gaap	Interest Expense InterestExpense	853000
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43743000
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30173000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-80520000
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-60159000
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	96000
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	35000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	211000
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	74000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-43839000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-30208000
	us-gaap	Net Income Loss NetIncomeLoss	-80731000
	us-gaap	Net Income Loss NetIncomeLoss	-60233000
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.92
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.92
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.69
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.36
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.36
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47882
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47882
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45680
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45680
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	47686
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	47686
	us-gaap	Net Income Loss NetIncomeLoss	-60233000
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-306000
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-465000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-43839000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-30208000
	us-gaap	Net Income Loss NetIncomeLoss	-80731000
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-20000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-771000
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-29000
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44145000
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30228000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-81502000
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60262000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	374081000
CY2022Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2063000
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1660000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5006000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-36892000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	345453000
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1042000
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7414000
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-306000
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-43839000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	309764000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	328609000
CY2021Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	1838000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	380000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5852000
CY2021Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-9000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-30025000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	306645000
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	149085000
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1723000
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3937000
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-20000
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-30208000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	431162000
	us-gaap	Net Income Loss NetIncomeLoss	-80731000
	us-gaap	Net Income Loss NetIncomeLoss	-60233000
	us-gaap	Share Based Compensation ShareBasedCompensation	12420000
	us-gaap	Share Based Compensation ShareBasedCompensation	9789000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2586000
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2553000
	om	Non Cash Lease Expense NonCashLeaseExpense	544000
	om	Non Cash Lease Expense NonCashLeaseExpense	501000
	om	Non Cash Interest Expense NonCashInterestExpense	282000
	om	Non Cash Interest Expense NonCashInterestExpense	282000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2509000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1035000
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-435000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	101784000
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	19900000
	om	Provision For Inventories ProvisionForInventories	808000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-34706000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-9153000
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-1538000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	15311000
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	12116000
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-70000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-76910000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-69457000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3475000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1766000
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	133015000
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	122401000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-104267000
	om	Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases	4765000
	om	Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases	3941000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	149085000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4765000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	153026000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-106851000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20698000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	215659000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	328283000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	108808000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	307585000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	283000
	us-gaap	Income Taxes Paid IncomeTaxesPaid	42000
	us-gaap	Interest Paid Net InterestPaidNet	621000
	us-gaap	Interest Paid Net InterestPaidNet	149000
	om	Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities	548000
	om	Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities	360000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1613000
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	92000
	om	Transfer Of Inventories To Property And Equipment TransferOfInventoriesToPropertyAndEquipment	0
	om	Transfer Of Inventories To Property And Equipment TransferOfInventoriesToPropertyAndEquipment	1294000
CY2021Q2	us-gaap	Restricted Cash RestrictedCash	33311000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108808000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	307585000
CY2021Q4	om	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	574000
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1745000
	us-gaap	Net Income Loss NetIncomeLoss	-80700000
	us-gaap	Net Income Loss NetIncomeLoss	-60200000
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-706700000
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	262100000
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	33300000
CY2022Q2	om	Cash Cash Equivalents Restricted Cash And Short Term Investments CashCashEquivalentsRestrictedCashAndShortTermInvestments	295400000
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25057000
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25216000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	55607000
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48132000
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	8000000.0
CY2022Q2	om	Revenue Performance Obligation1 RevenuePerformanceObligation1	7800000
CY2022Q2	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P12M
CY2022Q2	om	Revenue Performance Obligation1 RevenuePerformanceObligation1	200000
CY2022Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1700000
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4200000
	om	Debt Securities Available For Sale Remaining Contractual Maturities Period DebtSecuritiesAvailableForSaleRemainingContractualMaturitiesPeriod	one month to thirteen months
CY2022Q2	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	18000000.0
	om	Unrealized Losses Caused By Changes In Market Interest Rates UnrealizedLossesCausedByChangesInMarketInterestRates	89000
CY2022Q2	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
	us-gaap	Other Than Temporary Impairment Loss Debt Securities Available For Sale Recognized In Earnings OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSaleRecognizedInEarnings	0
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	33300000
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	33300000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1269000
CY2022Q2	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	3737000
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	33311000
CY2021Q4	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	3121000
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6762000
	om	Cash Cash Equivalents And Restricted Cash CashCashEquivalentsAndRestrictedCash	<p style="text-indent:5.067%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands):</span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.485%;"/> <td style="width:1.485%;"/> <td style="width:1.0%;"/> <td style="width:13.151%;"/> <td style="width:1.0%;"/> <td style="width:1.485%;"/> <td style="width:1.0%;"/> <td style="width:13.395%;"/> <td style="width:1.0%;"/> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Calibri;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">June 30,</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2022</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">2021</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Cash and cash equivalents</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">75,497</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">274,274</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Restricted cash</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">33,311</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">33,311</span></p></td> <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> <tr style="height:10.0pt;"> <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">108,808</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">$</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">307,585</span></p></td> <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"/> </p></td> </tr> </table>
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	75497000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	274274000
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	20731000
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	18114000
CY2022Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	9434000
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	6054000
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	23524000
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	15017000
CY2022Q2	us-gaap	Inventory Net InventoryNet	53689000
CY2021Q4	us-gaap	Inventory Net InventoryNet	39185000
CY2022Q2	om	Accrued Inventory Current AccruedInventoryCurrent	9904000
CY2021Q4	om	Accrued Inventory Current AccruedInventoryCurrent	4808000
CY2022Q2	om	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	1113000
CY2022Q2	om	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	23261000
CY2021Q4	om	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	13789000
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	30000000
CY2021Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	30000000
CY2022Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	194000
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	238000
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	29806000
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	29762000
CY2022Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	1000000
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	-0
CY2022Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	28806000
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	29762000
	om	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod	0.50
	om	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod	0.50
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7414000
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3937000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12420000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9789000
CY2022Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4608000
CY2021Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5216000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4608000
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5216000

Files In Submission

Name	View Source	Status
0000950170-22-013857-index-headers.html	Edgar Link	pending
0000950170-22-013857-index.html	Edgar Link	pending
0000950170-22-013857.txt	Edgar Link	pending
0000950170-22-013857-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
om-20220630.htm	Edgar Link	pending
om-20220630.xsd	Edgar Link	pending
om-20220630_cal.xml	Edgar Link	unprocessable
om-20220630_def.xml	Edgar Link	unprocessable
om-20220630_htm.xml	Edgar Link	completed
om-20220630_lab.xml	Edgar Link	unprocessable
om-20220630_pre.xml	Edgar Link	unprocessable
om-ex31_1.htm	Edgar Link	pending
om-ex31_2.htm	Edgar Link	pending
om-ex32_1.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OM
Outset Medical, Inc. Stock $om

2022 Q3 Form 10-Q Financial Statement

#000095017022013857 Filed on August 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OM Outset Medical, Inc. Stock $om

2022 Q3 Form 10-Q Financial Statement

#000095017022013857 Filed on August 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OM
Outset Medical, Inc. Stock $om